bevacizumab intravitreal (Pending FDA Approval)

Brand and Other Names:Lytenava, bevacizumab-vikg
  • Print
Sections

Dosing & Uses

Macular Degeneration

Pending FDA approval of neovascular (wet) age-related macular degeneration (AMD)

Next:

Pharmacology

Mechanism of Action

Binds and prevents activation of vascular endothelial growth factors (VEGF-A) and placental growth factor (PIGF)

Activation of VEGF-A and PIGF can result in neovascularization and vascular permeability

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.